Genzyme sues Impax over Renvela ANDA
09 April 2009
Nancy Faigen
Genzyme has filed a patent infringement suit in the US District Court for the District of Maryland against
Impax Laboratories regarding its submission of an ANDA for a generic version of the phosphate binder Renvela (sevelamer carbonate) 800mg tablets, thus triggering a 30-month Hatch-Waxman stay...
Please Login to read the full article.
09 April 2009
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- Sun set for generic Uroxatral ER launch in US with 180-day exclusivity
- Glenmark settles with Genzyme and Daiichi Sankyo over US Welchol generics
- Watson beatsTeva on appeals overgeneric Seasonique: sued by Novartis over Exelon
- Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
COMMENT
Other Informa Comment
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
